ALTAVILLA, AMELIA
 Distribuzione geografica
Continente #
AS - Asia 1.178
NA - Nord America 465
EU - Europa 256
SA - Sud America 111
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.049
Nazione #
US - Stati Uniti d'America 454
SG - Singapore 431
CN - Cina 395
HK - Hong Kong 123
BR - Brasile 90
VN - Vietnam 86
KR - Corea 85
DE - Germania 57
IT - Italia 48
NL - Olanda 38
FI - Finlandia 25
IN - India 24
SC - Seychelles 23
GB - Regno Unito 19
SE - Svezia 17
FR - Francia 16
JP - Giappone 14
AR - Argentina 11
AT - Austria 8
IE - Irlanda 8
CI - Costa d'Avorio 7
ID - Indonesia 5
MX - Messico 5
RU - Federazione Russa 5
ES - Italia 4
BD - Bangladesh 3
CA - Canada 3
CO - Colombia 3
IQ - Iraq 3
BE - Belgio 2
BG - Bulgaria 2
CH - Svizzera 2
CL - Cile 2
EC - Ecuador 2
HN - Honduras 2
MA - Marocco 2
PL - Polonia 2
TG - Togo 2
TR - Turchia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EG - Egitto 1
JO - Giordania 1
LT - Lituania 1
MY - Malesia 1
PH - Filippine 1
PY - Paraguay 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UA - Ucraina 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.049
Città #
Singapore 315
Hefei 200
Hong Kong 123
Santa Clara 111
Ashburn 97
Seoul 85
Beijing 54
Boardman 44
Ho Chi Minh City 29
Chandler 27
Buffalo 24
Los Angeles 21
Helsinki 20
Hanoi 19
Bengaluru 18
Munich 16
Tokyo 14
Bologna 11
Falkenstein 11
Frankfurt am Main 10
Nuremberg 9
Dublin 8
Abidjan 7
New York 7
Shanghai 7
London 6
Rio de Janeiro 6
Rome 6
Shenzhen 6
Tongling 6
Düsseldorf 5
Redondo Beach 5
Chicago 4
Da Nang 4
Dallas 4
Princeton 4
Salt Lake City 4
Baghdad 3
Bexley 3
Changsha 3
Guangzhou 3
Jakarta 3
Lang Son 3
Lappeenranta 3
Milan 3
Santo André 3
Tampa 3
Vũng Tàu 3
Wuhan 3
Ankara 2
Ann Arbor 2
Bari 2
Berlin 2
Bern 2
Bolzano 2
Brooklyn 2
Brussels 2
Cao Lanh 2
Caxias do Sul 2
Charlotte 2
Curitiba 2
Denver 2
Des Moines 2
Dongguan 2
Florianópolis 2
Fort Worth 2
Genoa 2
Groningen 2
Haiphong 2
Harbin 2
Huntington 2
Lauterbourg 2
Lomé 2
Natal 2
Nha Trang 2
Orem 2
Recife 2
Rezzato 2
Ribeirão das Neves 2
Salvador 2
San Francisco 2
Seattle 2
Shaoxing 2
Shijiazhuang 2
Sofia 2
Southend 2
São Paulo 2
Toronto 2
Turin 2
Turku 2
Vienna 2
Vĩnh Tường 2
Agadir 1
Alegrete 1
Alfenas 1
Almirante Tamandaré 1
Amman 1
Amsterdam 1
Aracaju 1
Aracruz 1
Totale 1.477
Nome #
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 160
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 122
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 118
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 110
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 108
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 87
PATIENT'S ATTITUDES TOWARDS TREATMENT IN ADVANCED CANCER: HOW THESE ARE IDENTIFIED FROM THEIR PHYSICIAN? 83
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) 74
RELATIONSHIP BETWEEN ENZALUTAMIDE ACTIVITY AND PREVIOUS ANTIANDROGEN WITHDRAWAL SYNDROME (AWS) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 72
BENEFIT OF POST-DOCETAXEL TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH POOR PERFORMANCE STATUS 70
KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 63
Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC) 60
ERLOTINIB RELATED TOXICITY IN ELDERLY PATIENTS AFFECTED BY NON-SMALL CELL LUNG CANCER (NSCLC) 54
CAR-T cell therapy: A potential new strategy against prostate cancer 53
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 53
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 46
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses 44
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 43
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents 41
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 40
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate 40
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 39
Visceral disease in castration-resistant prostate cancer 38
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 37
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 37
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 37
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone 32
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies 32
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma 32
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 31
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation 29
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 28
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 26
Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney 21
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 20
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 16
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 16
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma 15
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone 14
Clinical and pathological features of primary renal synovial sarcoma: Analysis of 64 cases from 11 years of medical literature 14
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert 14
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules 14
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 13
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view 12
null 2
Totale 2.110
Categoria #
all - tutte 6.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.126


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 0 0 0 6 1 1 10 12 9
2022/202362 4 10 2 10 7 9 0 1 11 0 3 5
2023/202440 2 3 1 0 1 6 0 15 5 1 2 4
2024/2025875 55 84 41 46 175 54 34 27 7 67 46 239
2025/20261.094 191 302 180 206 212 3 0 0 0 0 0 0
Totale 2.110